ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2010

Erdheim-Chester Disease: A Monocentric Series Of 96 Patients

Julien Haroche1, Laurent Arnaud1, Fleur Cohen-Aubart1, Baptiste Hervier1, David Saadoun1, Nathalie Costedoat-Chalumeau2, Sophie Besnard3, Kim Heang Ly4, Michel Pavic5, Jean-Gabriel Fuzibet6, Loic Raffray7, Laurent Aaron8, Pascal Bindi9, António Marinho10, Bjorn Blomberg11, Juan Salvatierra12, Claudia Dechant13, Aude Rigolet14, François Lifermann15, Jo Caers16, Catherine Veyssier-Belot17, Bertrand Wechsler18, Lucienne Michaux19, Giorgio Graziani20 and Zahir Amoura1, 1Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 2Internal Medicine, Hopital Cochin, Paris, France, 3Internal Medicine, Pontchaillou University Hospital, Rennes, Rennes, France, 4CHU Dupuytren, Limoges, Limoges, France, 5Internal Medicine, HIA Desgenettes, Lyon, France, Lyon, France, 6Internal Medicine, Internal Medicine, Hôpital de l'Archet 1, CHU de Nice, Nice, France, 7Internal Medicine, CHU de Bordeaux, Bordeaux, France, 8Internal Medicine, Hôpital Jacques Coeur, Bourges, Bourges, France, 9Internal Medicine, Department of medicine A, Centre Hospitalier de Verdun, Verdun, France, 10Unidade de Imunologia Clínica, Porto, Portugal, 11Internal Medicine, University of Bergen, Norway, Bergen, France, 12Rheumatology, University Hospital San Cecilio, Granada, Spain, 13Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, 14Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 15Internal Medicine, CH Côte d'Argent, Dax, Dax, France, 16Department of Clinical Hematology, Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman, Liège, Belgium, 17Internal Medicine, CHI Poissy Saint-Germain-en-Laye, Saint-Germain-en-Laye, France, 18Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 19Hematology, Cliniques Universitaires Saint-Luc UCL Bruxelles, Bruxelles, Belgium, 20Internal Medicine and Nephrology, Istituto Clinico Humanitas IRCCS, Rozzano-Milano, Italy, Milan, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Erdheim-Chester disease and interferons

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by an infiltration of foamy CD68+ CD1a- histiocytes. More than 500 cases of this disease have been reported since its first description in 1930.

Methods:

The aim of this study was to describe a single-centre series of 96 consecutive ECD patients hospitalized at least once between 1992 and 2013 in the departement of internal medicine of Pitié-Salpêtrière hospital, Paris, France.

The geographic origin of patients referred to our tertiary care centre is international: 75 are french residents, while 21 patients come from Germany, UK, Eire, Belgium, Spain, Portugal, Israel, Norway and South Africa.

Results:

Patients were 75 men and 21 women. Median age at diagnosis was 54.6 years (5-81 yr). In the present series the mean diagnostic delay is 2 yr (0-35yr). Mean follow-up between diagnostic and last news is 37.3 months (1.63-376 months). Fifty-five patients (56%) had peri-renal. Forty patients (42%) had a peri-aortic sheathing of the whole aorta (“coated aorta”), 33 (34%) a pericardial involvement, 29 (30%) a coronary involvement, 20 (21%) a reno-vascular hypertension, 34 (35%) a pseudotumoral infiltration of the right atrium. Twenty-two patients (23%) had an exophthalmos, 24 (25%) a xanthelasma often in peri-orbital spaces, 29 (30%) a diabetes insipidus, and 38 (40%) an involvement of the central nervous system (CNS), among which 17 (18%) with a cerebellar involvement. Twenty-one patients (22%) had hydronephrosis, 35 (36%) a pulmonary involvement, often asymptomatic. Seventy-four patients (80%) had high C-reactive protein values.

Eighty-seven patients (91%) have been treated with interferon alpha (IFNα) or Pegylated IFNα, with high doses when facing CNS and/or cardiac involvements. Twenty-two patients died (23%). We were able to identify a BRAFV600E mutation among 27 of the 53 patients (51%) among which tissue samples were exploitable. Seven of these patients with multisystemic ECD, refractory and/or intolerant to IFNα, have been treated with BRAF inhibitors (vemurefenib) with spectacular and sustained responses.

Conclusion:

We report the world largest’s monocentric series of ECD patients. The prognosis, which largely depends on the presence of CNS involvement, is variable. First line of treatment remains IFNα, which use is associated with improved survival in ECD is an independent prognostic factor of survival of ECD. Nevertheless, long-term therapy with IFNα may be poorly tolerated, and the place of BRAF inhibition, particularly for BRAFV600E mutated patients with life-threatening forms of the disease, should be studied in larger scale.


Disclosure:

J. Haroche,
None;

L. Arnaud,
None;

F. Cohen-Aubart,
None;

B. Hervier,
None;

D. Saadoun,
None;

N. Costedoat-Chalumeau,
None;

S. Besnard,
None;

K. H. Ly,
None;

M. Pavic,
None;

J. G. Fuzibet,
None;

L. Raffray,
None;

L. Aaron,
None;

P. Bindi,
None;

A. Marinho,
None;

B. Blomberg,
None;

J. Salvatierra,
None;

C. Dechant,
None;

A. Rigolet,
None;

F. Lifermann,
None;

J. Caers,
None;

C. Veyssier-Belot,
None;

B. Wechsler,
None;

L. Michaux,
None;

G. Graziani,
None;

Z. Amoura,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/erdheim-chester-disease-a-monocentric-series-of-96-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology